Category Archives: New York Stem Cells

image:5 days after infection, SARS-CoV-2 antigen (brown staining) is dispersed throughout the lung tissue of aged mice, leading to severe disease and death. view more

Credit: 2022 Beer et al. Originally published in Journal of Experimental Medicine. https://doi.org/10.1084/jem.20220621

Researchers in Germany have discovered that age-dependent impairments in antiviral interferon proteins underlie the increased susceptibility of older patients to severe COVID-19. The study, published today in the Journal of Experimental Medicine (JEM), shows that aged mice infected with SARS-CoV-2 are protected from severe disease by treatment with one of these interferons, IFN-.

The immune systems response to SARS-CoV-2 is coordinated by a group of antiviral signaling proteins called interferons, which help to stop the virus replicating and activate various immune cells that can clear the virus from the body. There are three different types of interferon protein, known as types I, II, and III, and researchers have estimated that up to 20% of SARS-CoV-2related deaths may be attributed to defects in type I interferon signaling (due to the presence of genetic mutations or autoantibodies that block type I interferons from functioning properly).

However, whether age-dependent changes in the activity of interferons explain why older patients are more susceptible to developing severe COVID-19 has remained unclear.

To investigate this question, a team of researchers led by Dr. Daniel Schnepf and Professor Martin Schwemmle at the Institute of Virology, Medical Center University of Freiburg, developed a novel strain of SARS-CoV-2 that, unlike clinical strains of the virus, can infect regular laboratory mice and cause severe disease. The strain, which carries several key mutations also found in omicron strains, was particularly virulent in aged mice, showing enhanced replication and causing increased death in older animals compared with younger ones.

We found that adult animals mounted a rapid and well-orchestrated innate and adaptive immune response to viral infection, whereas aged animals showed a reduced, delayed, and more pro-inflammatory response, explains Schnepf.

Schnepf and colleagues determined that type I interferon signaling was impaired in aged mice. Notably, however, the researchers also discovered that levels of the type II interferon IFN- were reduced in older animals infected with SARS-CoV-2. Treating these aged mice with IFN- protected them from severe illness and death in response to SARS-CoV-2 infection. In contrast, blocking type II interferon signaling in younger mice made them more susceptible to severe disease.

Collectively, our data suggest that impaired type I IFN signaling in combination with impaired IFN-mediated immune responses can account for the observed high SARS-CoV-2 disease susceptibility of aged mice, and possibly older humans, too, Schnepf says.

Finally, the researchers examined mice that are extremely susceptible to severe COVID-19, namely aged mice that are also genetically deficient in type I interferon signaling. Schnepf and colleagues found that, because type III interferons can partially substitute for the absence of type I interferon signaling, combined treatment with IFN- and the type III interferon IFN- was able to protect these high risk animals from severe illness and death.

By generating and employing a mouse model for severe COVID-19, we have identified the age-dependent impairment of type I and type II interferon responses as a critical pathomechanism that drives the virulence of SARS-CoV-2 in aged hosts, says Professor Schwemmle. We were able to successfully translate this novel insight into an immunomodulatory treatment strategy that prevented SARS-CoV-2induced lethality in a highly susceptible disease model that mimics impaired type I interferon immunity and advanced age.

Beer et al. 2022. J. Exp. Med. https://rupress.org/jem/article-lookup/doi/10.1084/jem.20220621?PR

# # #

About Journal of Experimental Medicine

Journal of Experimental Medicine (JEM) publishes peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. All editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board. Established in 1896, JEM is published by Rockefeller University Press, a department of The Rockefeller University in New York. For more information, visit jem.org.

Visit our Newsroom, and sign up for a weekly preview of articles to be published. Embargoed media alerts are for journalists only.

Follow JEM on Twitter at @JExpMed and @RockUPress.

Journal of Experimental Medicine

Experimental study

Animals

Impaired immune response drives age-dependent severity of COVID-19

21-Sep-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original:
Severe COVID-19 caused by senile interferon response in older patients, researchers suggest - EurekAlert

Funding rounds this week will help Arsenal and ILiAD move forward with their lead programs, while a philanthropic donation will allow UC San Diego to advance its space-based stem cell research.

UC San Diegos Largest Single Gift Earmarked for Stem Cell, Regenerative Medicine Research

After receiving a $150 million donation from businessman and philanthropist T. Denny Sandford, theUniversity of California, San Diego,announcedTuesday that it would use these funds to boost its stem cell and regenerative medicine research.

The stem cell studies, in particular, will be conducted aboard the International Space Station, allowing researchers to better understand the impacts of aging on stem cells and how this may prompt cells to become cancerous. Space-related research could yield better therapies not just for cancers but for diseases like Alzheimers and Parkinsons, as well.

Sanford also donated $100 million in 2013, allowing UCSD to establish the Sanford Stem Cell Clinical Center. His donations also enabled UCSD to create the T. Denny Sanford Institute for Empathy and Compassion in 2019.

Arsenals Programmable Cell Therapies Win $220M in Series B

Arsenal Biosciencesclosedits Series B round of financing Tuesday and reported earnings of $220 million. The privately held company will use these proceeds to bolster research into its programmable cell therapies and deepen its pipeline of solid tumor candidates across a wide range of cancers. Arsenal gained new investors during the oversubscribed funding round, including Bristol-Myers Squibb Company, Hitachi Ventures and Emerson Collective Investments.

Alongside its Series B round, the California-based company is preparing to initiate clinical studies for AB-1015, its lead candidate for ovarian cancer. Arsenal aims to clear an Investigational New Drug application and dose the first AB-1015 patient later this year.

Arsenal also welcomes Valentin (Vali) Barsan, M.D., attending pediatric oncologist at the Stanford University School of Medicine and an investor for SoftBank Investment Advisers, into its board of directors.

Class D Funding Pumps $42M into ILiADs Pertussis Shot

The company announced Tuesday that its recent Class D round of financingearnediLiAD Biotechnologies$42.8 million in proceeds. Family office hedge fund Knott Partners led the Class D round.

The New York biotech is channeling almost all of these funds into BPZE1, its next-generation pertussis vaccine candidate, establishing and improving the manufacturing process for BPZE1, as well as supporting its research and development.

In particular, the earnings will allow LiAD to proceed with a Phase IIb human challenge study to assess if BPZE1 can prevent the nasopharyngeal colonization ofBordetella pertussis.

To date, more than $100 million have already gone into the research and development of BPZE1. The candidate has cleared four human clinical studies and has been granted the FDAs Fast Track designation.

ILiAD also plans on using its earnings to power its current operations.

View original post here:
Money on the Move: Arsenal, ILiAD and a Hefty Gift to UCSD - BioSpace

Liya Shuster-Bier had always been a high achiever. The 34-year-old Soviet Union refugee immigrated to New York with her parents in 1989. She attended Dartmouth on a scholarship and throughout her 20s worked at Goldman Sachs and a social impact startup in Boston, and completed her MBA at Wharton.

"All that was on my radar was the next exam, the next internship, the next job," she says. But in January 2018, six months after graduating from Wharton, she learned she had a rare form of non-Hodgkin lymphoma, a cancer that affects the body's immune system.

"Suddenly, me turning 30 was no longer a guarantee," she says.

Her year-and-a-half-long battle with the disease would ultimately change her priorities in life and attitude toward work completely.

When she was first diagnosed, Shuster-Bier was working at philanthropic fundraising company the Overton Project.

She went through six rounds of chemotherapy to eliminate the cancer, trying to maintain a normal life and work schedule even as the procedure landed her in the hospital. "I was literally taking the six train to Soho with chemo strapped to me," she says.

Though by summer it seemed Shuster-Bier's life could get back to normal, that October, the cancer came back. Now, treatment would require both radiation and a stem cell transplant which would force her to put a pause on life.

A stem cell transplant is, "a procedure in which a patient receives healthy stem cells (blood-forming cells) to replace their own stem cells that have been destroyed by treatment with radiation or high doses of chemotherapy," according to the National Cancer Institute.

"My doctor made me sign an affidavit that I would not work during the 100 days that I was a bubble girl after the transplant," says Shuster-Bier, who went on medical leave. This wasn't just because her doctor wanted to ensure that Shuster-Bier rested. The treatment is so aggressive she couldn't function on an elemental level.

Shuster-Bier recovering from her stem cell transplant in the Hudson Valley in 2019.

Courtesy Liya Shuster-Bier

"I could not walk around the block," she says, "I just didn't have the lung capacity." Reading was a challenge. Math was a challenge.

"The concept of checking email was laughable," she says.

Even as she tried to heal, that period set off a mini crisis.

She'd so long invested most of her time producing, without work, "I was like, who am I?" she says. But it also made her start to question this attitude. She'd text her friends to take a walk or watch some Netflix and realize people were working as late as 8 p.m.

"We are literally spending the vast majority of our awake hours and the vast majority of our time at work," she says she thought. "For what?"

Shuster-Bier realized her way of life, "was literally just destroying me," she says. "Destroying my health, destroying my mental state, pushing me to the brink." As she regained her strength, she began paying attention to how much she slept, what she ate and how much time she spent with her husband. She even reexamined her spirituality.

"I started to see a new Rabbi," she says.

Instead of "destruction," she thought about a new attitude toward life, "How do I actually pivot to nourishment?"

Shuster-Bier's mother had landed in remission from breast cancer just months before Shuster-Bier was diagnosed herself. Both experiences made her realize that beating the disease is not just about treating the cancer but about managing the symptoms following treatment.

Shuster-Bier recovering from chemotherapy in 2018.

Courtesy Liya Shuster-Bier

"No one was helping me manage my constipation, my headaches, my dehydration," she says, adding that, "I was motivated to start a place where this all existed."

Shuster-Bier went back to the Overton Project after recovering from the transplant but within months founded Alula, a product marketplace for patients navigating these and other symptoms. She began working on it full-time in December 2019. The cancer forced her to go into medically induced menopause, and she and her husband agreed that she could invest the money they had saved for starting a family to found the company. She's also raised $2 million to run it since.

Though the life of an entrepreneur is traditionally nonstop and hectic (25 hours per day if you ask Kevin O'Leary), Shuster-Bier has continued applying the attitude she built after treatment and focuses on nourishment and health.

Instead of being out until 11 p.m. and back at her desk by 5 a.m., as she'd sometimes done in the past, she wakes up naturally every day between 5:30 and 7:45. She starts her workday at 10 a.m. and finishes no later than 6 or 7. She makes ample time for her husband, puppy and friends, and for taking walks and cooking.

"The new compass for me," she says, is "what feeds your being versus what feeds your doing?" Three years into remission, the new attitude appears to be working.

Check out:

Exercise 2-4x more than the HHS recommends to achieve maximum benefit, says new study

Want better sleep? Try 5 foods naturally rich in melatonin

4 entrepreneurs who've raised millions on the morning routines that set them up for success

Sign up now: Get smarter about your money and career with our weekly newsletter

Go here to see the original:
How surviving cancer changed this 34-year-olds attitude toward work: The concept of checking email was laughable - CNBC

Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced the appointment of Roger Sawhney, M.D., as Chief Financial Officer. Dr. Sawhney previously served as Chief Financial Officer and Chief Business Officer at Omega Therapeutics, a pioneer in mRNA-based therapeutics for precision gene modulation.

"The Garuda team is so pleased to have Roger join in our efforts to democratize blood stem cell transplants and ensure this vital, and often curative, therapy is made accessible to eligible patients in need," said Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer of Garuda. "Roger's experience in biopharma and health care investing coupled with his expertise in operational management and commercialization will be instrumental in helping to advance our efforts to create off-the-shelf, durable blood stem cell therapies."

Most recently, Dr. Sawhney served as Chief Financial Officer and Chief Business Officer at Omega Therapeutics, where he led finance, strategy, business development and data/analytics. During his tenure at Omega, Dr. Sawhney led capital raises of more than $300M, including Omega's crossover round and initial public offering. Prior to Omega, Dr. Sawhney served in a variety of prestigious roles including Partner at Bain Capital and Boston Consulting Group. He was also a Director at KKR in health care private equity and growth equity investing and Senior Vice President and Global Head of Corporate Strategy at Novartis, Basel. Dr. Sawhney has held board appointments for Ebb Therapeutics, New York Institute of Technology and Arcellx, Inc. He received his M.D. at Harvard Medical School and an B.A. in Economics with Distinction at Stanford University.

Garuda's platform for generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched, transgene-free blood stem cell therapies. Currently, patients seeking a blood stem cell transplant must find a suitable human donor as a source of blood stem cells. Racial minority patients face greater barriers than white patients in finding suitable blood stem cell matches. Like bone marrow transplants, Garuda's technology has the potential to address, and possibly cure, more than 70 diseases.

"I am absolutely thrilled to join Garuda to help bring this potentially life changing therapy to patients," Dr. Sawhney said. "Eliminating the need for donor or patient cells while gaining the ability to exploit stem cell engineering would democratize blood stem cell transplants and has potential to revolutionize cell therapy."

About Garuda TherapeuticsGaruda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases. https://garudatx.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005141/en/

See more here:
Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer - Benzinga

What we put in our bodiesfoodis regulated by the Food and Drug Administration and the U.S. Department of Agriculture.

What we put on itskin care and beauty productsis not.

That could be an issue.

In one 2021 report, scientists tested 231 popular makeup products from the U.S. and Canada and found that more than 100 had Per-and poly-fluoroalkyl substances (PFAS). These are chemicals that dont break down and build up in the body over time.

They include perfluorooctanoic acid, which may cause cancer, according to the American Cancer Society.

Clean skin goes beyond washing your face.

Your skin is a living, dynamic organ, says Nava Greenfield, M.D. of Schweiger Dermatology Group in New York City. Just like you consider carefully what you put into your mouth, you should take care in what you place on your skin.

Understanding whats in your products can help you achieve long-term health thats more than skin-deep.

Heres what the science says you should avoidand what to use instead.

The skin is our largest organ, notes Marianna Blyumin-Karasik, board-certified dermatologist, co-founder of Precision Skin Institute, and founder of Stamina Cosmetics.

The skin has high absorption, so skin care products that can be absorbed and enter our bloodstream can have detrimental effects on our overall health, Blyumin-Karasik says.

Some ingredients like synthetic or highly concentrated fragrances or chemicals in personal care products can trigger skin sensitivity, irritation, or a more intense allergy.

Symptoms can include:

Other ingredients have been linked to more serious problems, like:

For example, a 2018 review suggested that phthalates found in certain personal care products could adversely affect male fertility.

A 2021 study indicated that exposure to formaldehyde, sometimes used in keratin hair treatments, could lead to heart malformations in a developing fetus.

In 2020, California became the first state to issue a statewide ban on 24 chemicals, including methylene glycol and formaldehyde.

Other states dont have these bans, leaving consumers to analyze and interpret labels themselves.

Complicating things, some recommendations to avoid specific ingredients arent one-size-fits-all. Different people may have different (or no) reactions to certain ingredients, even if theyre common allergens.

Aside from real toxins and dangerous chemicals, a list like this will be different for each person, Greenfield says. Unfortunately, its not all black and white.

Having an idea of whats potentially toxic and whats more likely to cause skin irritation can help you make informed decisions about the products you choose.

From common allergens to potential carcinogens, here are the ingredients Blyumin-Karasik and Greenfield suggest avoiding:

Blyumin-Karasik and Greenfield warn that PEGs are a potential skin irritant.

Theyre most often found in lotions, creams, and hair products because they can act as skin conditioners and humectants, a common moisturizing agent.

A small 2021 case study examined six cases of acute sensitivity to PEGs. However, researchers also noted the allergy was rare.

Blyumin-Karasik notes that methyl and propyl parabens are preservatives with reputations for being hormone disruptors. However, research is mixed.

A 2017 study on gerbil prostates indicated that methylparaben could disrupt estrogenic and androgenic receptors that might affect the prostate.

Another 2017 study suggested parabens, including methyl and propyl parabens, posed little health risk. However, researchers noted that parabens could inhibit compounds with anti-estrogenic properties.

The FDA wrote in 2022 that it didnt have enough evidence to warn that parabens affect human health. The American Academy of Dermatology (AAD) reported similarly in 2019, noting that allergic reaction risks were low.

Found in some eye make-up products, lipsticks, and deodorants, aluminum can cause skin irritation, according to Greenfield.

Theres also been discussion as to whether aluminum is a carcinogen, or cancer-causing agent.

A 2015 study suggested aluminum can increase the migration of breast cancer cells and called for more research.

In 2013, the Cosmetic Ingredient Review said alumina and aluminum hydroxide was safe to put in cosmetics, noting that it doesnt get absorbed into the skin and less than 1 percent is absorbed orally.

This ingredient is a preservative commonly found in soaps and shampoos and may cause skin irritation or allergies, Blyumin-Karasik explains. Greenfield agrees with avoiding formaldehyde, saying its a common irritant.

A 13-year retrospective study of patch tests published in 2020 indicated that a polymer known as toluene-sulfonamide-formaldehyde resin (R-TSF or TSFR), often used in nail polish, was one of the most common allergens. Its also known as a carcinogen, but data shows its only hazardous if a person inhales a significant amount.

The American Cancer Society says formaldehyde in personal care products like shampoos typically contains formaldehyde levels that are far below hazardous to health. The organization says keratin hair smoothing treatments can raise indoor air concentration to hazardous levels.

Phthalates are typically used to make sure plastic doesnt break. They can also be used in fragrances in skin products. Blyumin-Karasik warns they may disrupt hormones.

A 2020 literature review indicated that phthalates could lead to:

A 2018 study suggested phthalates could lead to pregnancy loss and fertility issues.

However, its important to note that neither piece of research above was specific to phthalates in beauty products.

Key West and Hawaii recently banned oxybenozone, which is commonly found in sunscreen. Blyumin-Karasik says it can disrupt hormones and cause allergic reactions.

A 2020 review of 29 studies indicated no a link between fertility issues and oxybenzone and called for more research.

However, an older 2016 study indicated that men with higher levels of benzophenone-type ultraviolet (UV) filter concentrations had lower sperm concentrations.

Avoiding fragranced products and using a mineral-based sunscreen can help avoid harmful chemicals, Blyumin-Karasik says. Looking for preservative-free items can also cut down on risks of irritants and health hazards.

The main purpose of preservatives is to maintain the integrity of the personal care products, Blyumin-Karasik says. The natural alternatives may not attain as long of the shelf-life as the chemical ones, but theyre better for our well-being.

To clean up your beauty regimen, Blyumin-Karasik suggests looking for products that contain these safer ingredients instead.

Blyumin-Karasik suggests using tea tree oil, an essential oil found in shampoos, skin care items, hand sanitizers, and first aid products.

A 2021 study suggested tea tree oil could help disinfect hands when used in sanitizer.

Research from 2015 indicated it could aid wound healing, and a 12-week pilot study published in 2017 suggested it could reduce acne.

Instead of PEGs, opt for a humectant with fewer potential side effects. Blyumin-Karasik recommends glycerin.

One small 2017 study of women indicated that products with a mix of hyaluronic acid, glycerin, and Centella asiatica (gotu kola) could boost skin hydration for 24 hours.

A 2019 safety assessment suggested glycerin was safe to use in cosmetic practices.

Coconut oil, or Cocus nucifera, is extracted from the meaty part of a coconut fruit.

Blyumin-Karasik recommends it because its moisturizing and can reduce mold growth in skin care products.

A 2022 study indicated that a coconut oil-based serum combined with deer antler stem cell extract for two weeks could:

A 2019 study indicated virgin coconut oil had anti-inflammatory properties and supported its use in skin care products.

Blyumin-Karasik says elderberry, or Sambucus nigra extract, often found in serums, has versatile benefits for our skin.

She notes these benefits include antimicrobial effects and high levels of vitamin C.

Research on elderberry is limited, particularly in topical products. However, a 2019 study suggested it had anti-aging benefits when ingested as a supplement.

Blyumin-Karasik says willow bark, or Salix nigra extract, is an excellent source of skin preservation. She recommends it for its anti-inflammatory and antimicrobial properties.

Besides that, willow bark contains a potent salicin ingredient which has gentle exfoliating properties to cleanse pores and reduce skin surface oil, she says.

A 2019 study suggested willow bark total extract may have antioxidant and anti-inflammatory benefits.

An older 2010 study suggested that salicin, which is extracted from white willow bark, may have benefits when applied to the skin topically.

When shopping for personal care products, there are a few things youll want to keep in mind, depending on your age and any conditions you have.

Leave the layering for sweater weather, not skin care. Blyumin-Karasik says the biggest issues she sees in her clinic happen when people try to cake on too many products or ingredients.

Trying to be innovative or frugal, young individuals play with potentially hazardous ingredients such as baking soda or lemon juice which can lead to significant skin irritation, Blyumin-Karasik says. Older individuals try to layer too many products onto their skin such alpha hydroxy acids and potent retinoids and as a result, create skin allergy or irritation.

Blyumin-Karasik recommends working with a dermatologist to find the correct ingredients for your skin type and beauty goals.

A long ingredients list doesnt necessarily mean there are a ton of items working to boost your skins health. Sometimes, simple ingredient lists are most effective.

In general, if a skin care product has too many chemicals or fragrances, it can irritate the skin and cause skin rashes, and its best to avoid, Blyumin-Karasik says.

Individuals with sensitive skin, eczema, dermatitis, or rosacea will want to pay particular attention to product labels and the less is more mantra, Blyumin-Karasik says, as people with these conditions are more prone to irritation.

Theyre best served by using fragrance-free, sensitive skincare lines such as Avene and Bioderma, and definitely avoiding any of the above skin allergens, Blyumin-Karasik says.

Blyumin-Karasik advises acne-prone individuals to opt for products that wont clog pores. She suggests looking for words like oil-free and noncomedogenic and minimizing the use of occlusive moisturizers or make-up.

These can cause more breakouts and blemishes, Blyumin-Karasik warns.

When purchasing skin care products, youre making an investment in your bodys largest organ.

But some ingredients may not serve your skin or overall health.

Though research in some cases is minimal and others are mixed, Phthalates and some parabens are linked to hormonal disruption. Other ingredients are carcinogens or may cause irritation.

Speaking with a dermatologist can help you figure out the best and safest products and ingredients for your skin and overall health.

Beth Ann Mayer is a New York-based freelance writer and content strategist who specializes in health and parenting writing. Her work has been published in Parents, Shape, and Inside Lacrosse. She is a co-founder of digital content agency Lemonseed Creative and is a graduate of Syracuse University. You can connect with her on LinkedIn.

Follow this link:
6 Ingredients to Avoid Putting on Your Skin - Healthline

Scientists have created the miracle of life no male or female necessary.

Using only a mixture of stem cells, University of Cambridge researchers were able to generate a live, synthetic mouse embryo complete with a brain and beating heart in what they deemed a world first.

It could have gone on to develop a spine, intestines and muscle and, eventually, become a live mouse.

Scientists observations from the experiment could provide life-saving insight into the mysteries of human development. For example, the research could help doctors better understand the causes of a miscarriage during the early stages of pregnancy or could inform the study of lab-grown organs that could be used in organ donation and might help address the current donor shortage.

Our mouse embryo model not only develops a brain, but also a beating heart, all the components that go on to make up the body, said lead author and professor, Magdalena Zernicka-Goetz in a statement. Its just unbelievable that weve got this far. This has been the dream of our community for years, and major focus of our work for a decade and finally weve done it.

The Cambridge lab began their experiment with three primary embryonic stem cells, throwing them into a favorable environment and nudging them toward each other, just close enough so they could communicate and encourage the formation of life.

Any and all cells liver cells, skin cells, blood cells, etc. begin as stem cells but soon differentiate in the embryo in order to build a complete living organism. Thats why theyre often referred to as master cells. As the embryo develops, some stem cells will manifest into organs, bones and other tissues, while others multiply into daughter cells that the body stores for later like, say, when we get an injury and need to generate new tissue for healing.

Those three embryonic stem cells had shown the fundamentals of successful development by starting to form a brain, heart and nutritional yolk sac but didnt survive beyond 8days just under half as long as it takes for a mouse to be born, about 20 days.

Scientists are a long way off from creating a living, breathing body entirely inside the lab, and without input from a mother and father, but thats not what this study is about. What Cambridge researchers observed in just over a week could be invaluable, they said, considering the estimated 20% to 50% of pregnanciesend in miscarriage, often before the mother has any idea shes pregnant.

Its an absolutely fantastically complex stage of development, and [our study] has extremely relevant meaning for the rest of our life, said Zernicka-Goetz during a press conference, according to Gizmodo.

If the Cambridge teams methods later prove successful with human tissue, they hope to apply them to creating lab organs for transplantation.

What makes our work so exciting is that the knowledge coming out of it could be used to grow correct synthetic human organs to save lives that are currently lost, said Zernicka-Goetz. It should also be possible to affect and heal adult organs by using the knowledge we have on how they are made.

Continued here:
Scientists create 'synthetic' embryo with brain, beating heart in 'world first' - New York Post

New York, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Kenneth Research has published a detailed market report on Global Cell Banking Outsourcing Market for the forecast period, i.e., 2022 2031, which includes the following factors:

Global Cell Banking Outsourcing Market Size:

The global cell banking outsourcing market generated the revenue of approximately USD 7200.1 million in the year 2021 and is expected to garner a significant revenue by the end of 2031, growing at a CAGR of ~18% over the forecast period, i.e., 2022 2031. The growth of the market can primarily be attributed to the development of advanced preservation techniques for cells, and increasing adoption of regenerative cell therapies for the treatment of chronic diseases such as cancer. Additionally, factors such as growing demand for gene therapy, and increasing worldwide prevalence of cancer are expected to drive the market growth. According to the World Health Organization, nearly 10 million people died of cancer across the globe in 2020. The most recurrent cases of deaths because of cancer were lung cancer which caused 1.80 million deaths, colon, and rectum cancer which caused 916 000 deaths, liver cancer which caused 830 000 deaths, stomach cancer which caused 769 000 deaths, and breast cancer which caused 685 000 deaths. Furthermore, it was noticed that about 30% of cancer cases in low and lower-middle income nations are caused by cancer-causing diseases such the human papillomavirus (HPV) and hepatitis.

Get a Sample PDF of This Report @ https://www.kennethresearch.com/sample-request-10070777

Global Cell Banking Outsourcing Market: Key Takeaways

Increasing Geriatric Population across the Globe to Boost Market Growth

Increasing demand for stem cell therapy, and increasing biopharmaceutical production are estimated to fuel the growth of the global cell banking outsourcing market. Among the geriatric population around the world, the demand of stem cell therapy is at quite a high rate. Hence, growing geriatric population across the globe is also expected be an important factor to influence the market growth. According to the data by World Health Organisation (WHO), the number and proportion of geriatric population, meaning the people aged 60 years and older in the population is rising. The number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050.

In addition to this, increasing prevalence of chronic diseases, supportive initiatives by governments around the world, and growing awareness about stem cell banking are predicted to be major factors to propel the growth of the market. The growth of the global cell banking outsourcing market, over the forecast period, can be further ascribed to the rising investments in the R&D activities to continuously bring up more feasible solutions for medical procedures. According to research reports, since 2000, global research and development expenditure has more than tripled in real terms, rising from approximately USD 680 billion to over USD 2.5 trillion in 2019.

Browse to access In-depth research report on Global Cell Banking Outsourcing Market with detailed charts and figures: https://www.kennethresearch.com/report-details/cell-banking-outsourcing-market/10070777

Global Cell Banking Outsourcing Market: Regional Overview

The global cell banking outsourcing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region.

Advanced Healthcare Facilities Drove Market in the North America Region

The market in the North America region held the largest market share in terms of revenue in the year 2021. The growth of the market in this region is majorly associated with the increasing number of pharmaceutical companies & manufacturers in the region, and increasing awareness for the use of stem cells as therapeutics. Increasing number of bone marrow and cord blood transplants throughout the region is also estimated to positively influence the market growth. It was noted that, 4,864 unrelated and 4,160 related bone marrow and cord blood transplants were performed in the United States in 2020.

Increasing Prevalence of Chronic Diseases to Influence Market Growth in the Asia Pacific Region

On the other hand, market in the Asia Pacific region is estimated to grow with the highest CAGR during the forecast period. The market in this region is driven by the increasing investment in biotechnology sector by government and private companies specifically in countries such as China, India, and Japan. Moreover, the increasing pool of patient with chronic diseases, such as cancer, and the ongoing research & development activities for cancer treatment is expected to propel the growth of the market. Further, increasing percentage of regional health expenditure contributing to the GDP is also estimated to be a significant factor to influence the growth of the cell banking outsourcing market in the Asia Pacific region. As per The World Bank, in the year 2019, share of global health expenditure in East Asia & Pacific region accounted to 6.67% of GDP.

Get a Sample PDF of the Global Cell Banking Outsourcing Market @ https://www.kennethresearch.com/sample-request-10070777

The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in:

Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Global Cell Banking Outsourcing Market, Segmentation by Bank Phase

The bank storage segment held the largest market share in the year 2021 and is expected to maintain its share by growing with a notable CAGR during the forecast period. The market growth is anticipated to be driven by the development of effective preservation technologies such as cryopreservation technique. Cryopreservation is a technique in which low temperature is used to preserve the living cells and tissue for a longer time. With the growing healthcare expenditure per capita across the world, demand for bank storage increasing notably. As sourced from The World Bank, in 2019, worldwide health expenditure per capita was USD 1121.97.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.kennethresearch.com/sample-request-10070777

Global Cell Banking Outsourcing Market, Segmentation by Product

The adult cell banking segment is estimated to hold a substantial market share in the global cell banking outsourcing market during the forecast period. The growth of this segment can be attributed to the significant prevalence of chronic diseases among the adults around the globe. For instance, according to the National Library of Medicine 71.8% of adult population suffered from cardiovascular diseases, 56% had diabetes, and 14.7% adults had arthritis as of 2020.

Global Cell Banking Outsourcing Market, Segmentation by Cell Type

Global Cell Banking Outsourcing Market, Segmentation by Bank Type

Few of the well-known market leaders in the global cell banking outsourcing market that are profiled by Kenneth Research are SGS SA, WuXi AppTec, LifeCell International Pvt. Ltd., BSL Bioservice, LUMITOS AG, Cryo-Cell International, Inc., REPROCELL Inc, CORDLIFE GROUP LIMITED, Reliance Life Sciences, and Clean Biologics and others.Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10070777

Recent Developments in the Global Cell Banking Outsourcing Market

Browse More Related Reports:

Immunoassays in R&D Market Segmentation by Application (Cancer Research, Infectious Diseases, Autoimmune Diseases, Endocrinology, and Others); by End-Use (Academic Laboratories & Institutions, Biotechnology & Pharmaceutical Companies, and Others); and by Product & Services (Analyzers, Software & Services, and Kits & Reagents)-Global Demand Analysis & Opportunity Outlook 2031

Global Vaginal Slings Market Segmentation by End-Use (Clinics, Hospitals, and Ambulatory Surgical Centers); and by Slings Type (Conventional, and Advanced Vaginal Slings)-Demand Analysis & Opportunity Outlook 2031

Chemotherapy Market Segmentation by Cancer Type (Lung, Breast, Stomach, and Ovarian Cancer, and Others); by Gender Type (Male, and Female); and by Product Type (Pump, Cannula, Catheter, and Others)-Global Demand Analysis & Opportunity Outlook 2022-2031

Lancet Market Segmentation by Type (Push Button Safety, Pressure Activated Safety, Personal, and Side Button Safety); by Application (Glucose Testing, Hemoglobin Testing, and Coagulation Testing); and by End Users (Homecare, Hospitals & Clinics, Blood Banks, and Others)-Global Demand Analysis & Opportunity Outlook 2031

eClinical Solutions Market Segmentation by Product Type {Clinical Data Management Systems (CDMS), Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), Electronic Clinic Outcome Assessment0 (eCOA), Randomization & Trial Supply Management (RTSM), Electronic Patient-Reported Outcome (ePRO), Electronic Trial Master File (eTMF), and Clinical Analytics Platform}; by Delivery Mode (Web-based, On-Premise, and Cloud); and by End users {Pharma & Biotech, Hospitals, and Contract Research Organizations (CROs)}-Global Demand Analysis & Opportunity Outlook 2031

About Kenneth Research

Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@kennethresearch.com

U.S. Phone: +1 313 462 0609

Web: https://www.kennethresearch.com/

Visit link:
Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell...

NEWARK, Del, Aug. 29, 2022 (GLOBE NEWSWIRE) -- As per Future Market Insights, the global pelvic reconstruction market was around US$ 270.5 Mn in 2021 and is projected to exhibit at CAGR of 2.8% over the forecast period (2022-2032), surpassing US$ 366.9 Mn in 2032. Growth is due to the increased use of vaginal mesh, slings, and pessaries in the healthcare sector owing to rising cases of pelvic floor disorders.

Furthermore, increasing awareness regarding vaginal health due to growing cases of pelvic disorders and deformities have surged the need for pelvic reconstruction products. On the back of this, key players are vying to develop systems that can be approved by regulatory authorities such as the FDA.

Additionally, growing acceptance of pelvic floor reconstruction procedures in hospitals and specialty clinics is prompting the adoption of advanced systems for accurate and speedy recovery. There is also an increase in the research and development on ways to handle pelvic floor disorders by mitigating the risk factors.

Request a Sample PDF Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15500

Increasing use of tissue engineering to support pelvic floor and also promotes tissue repair. This is also highly biocompatible compared to the general approach of using polypropylene mesh. Hence, several ongoing research is focusing on tissue engineering such as the use of fibroblasts and stem cells is supporting the growth in pelvic reconstruction market.

Key Takeaways from Market Study

Rising initiatives to promote safety and mitigate risk, as well as the increasing research and development for the improvement of treatment approaches is set to propel the sales of pelvic reconstruction products across the globe, says an analyst of Future Market Insights.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15500

Market Competition

The market for pelvic reconstruction consists of a number of local as well as established players within the market sphere. There is increased research and development to meet the current needs of the population.

Key Companies Profiled in the Study are

Talk to Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-15500

Key Market Segments Covered in Pelvic Reconstruction Market Research:

By Product:

By Procedure:

By Indication:

By Pelvic Organs:

By End User:

Table of Content

1.Executive Summary

1.1.Global Market Outlook

1.2.Demand Side Trends

1.3.Supply Side Trends

1.4.Analysis and Recommendations

2.Market Overview

2.1.Market Coverage / Taxonomy

2.2.Market Definition / Scope / Limitations

2.3.Inclusions and Exclusions

3.Key Market Trends

3.1.Key Trends Impacting the Market

3.2.Product Innovation / Development Trends

Get detailed TOC @ https://www.futuremarketinsights.com/toc/rep-gb-15500

Have a Look at Related Research Reports of Healthcare

Female Pelvic Implants Market Size : The female pelvic implants market is expected to surpass US$ 331.96 Mn by 2032.

Knee Reconstruction Devices Market Research : Global knee reconstruction devices market is expected to gain impetus from expanding geriatric populations & incidence of bone and joint ailments, expanding at a healthy CAGR of close to 6% through 2031.

Breast Reconstruction Surgery and Treatment Market Insights : The breast reconstruction surgery and treatment market are predicted to expand at a CAGR of 2.7% during the forecast period, with a predicted value of US$ 647 million in 2026.

Neurology Services Market Forecast : The global neurology services market is expected to reach a valuation of US$ 2,562.8 Bn by the end of 2022, and further expand at a CAGR of 5.4% from 2022 to 2032. The market is likely to reach a valuation of ~US$ 4,317.8 Bn by 2032.

Oxygen Conservation Devices Market Analysis : The oxygen conservation devices market is anticipated to have an effective CAGR of 11.1% during the period of 2022-2032.

About Us:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.comBrowse latest Market Reports:https://www.futuremarketinsights.com/reports

View original post here:
Pelvic Reconstruction Market is projected to reach a valuation of US$ 366.9 million by 2032, at a CAGR of 2.8% during 2022-2032 Future Market...

Kenneth Research

Key Companies Covered in the Global Mesenchymal Stem Cell (MSC) Market Research Report by Kenneth Research Are Cell Applications, Inc., Celprogen Inc., STEMCELL Technologies Inc., Axol Bioscience Ltd., Cytori Therapeutics Inc., Proteona Pte. Ltd., BrainStorm Cell Limited, Stemedica Cell Technologies, Inc., Mesoblast Ltd., ScienCell Research Laboratories, Inc., Neuromics, and other key market players.

New York, Aug. 04, 2022 (GLOBE NEWSWIRE) -- According to the World Health Organization, the number and percentage of the geriatric population, i.e., adults 60 years of age and older, is increasing. In 2019, 1 billion people were 60 years of age or older across the globe. This number is anticipated to increase to 1.4 billion by 2030 and to 2.1 billion by 2050. In addition to this, it was also observed that 85% of older persons have at least one chronic health issue, and 60% have two or more.

Kenneth Research has published a detailed market report on Global Mesenchymal Stem Cell (MSC) Market which includes the ongoing industry innovations and recent trends being adopted by the major industry players to achieve their business targets. Apart from that, the inclusive data on market size, growth rate, market revenue share, growth opportunities and challenges for the market players along with worldwide analysis on five major regions North America, Latin America, Europe, Asia Pacific and Middle East & Africa has been provided in the report.

According to the National Library of Medicine, globally, a significant 310 million major surgeries were performed each year as of 2020. Amongst them, around 40 to 50 million were done in USA and 20 million in Europe. The global mesenchymal stem cell (MSC) market generated revenue of around USD 3 billion in the year of 2021. The market is estimated to grow at a CAGR of ~14% over the forecast period, i.e., 2022-2031. The growth of the market can majorly be attributed to the increasing aging population who are prone to different types of diseases, growing awareness regarding the treatment of injuries and surgery procedures, and the rising usage of mesenchymal stem cells as a substitute surgery for knee replacement and other operative procedures. Moreover, the increasing cost of these procedures and surgeries is estimated to elevate the overall health expenditure across the globe and which in turn is estimated to be a prime factor to drive market growth during the forecast period. According to the data by The World Bank, in 2019, the global health expenditure accounted to 9.831% of the GDP.

Story continues

Get a Sample PDF of This Report @ https://www.kennethresearch.com/sample-request-10082369

Furthermore, increasing road accidents and deaths due to accidents around the world is another factor to drive the market growth over the forecast period. Most of the road accidents lead to severe or traumatic injuries which require surgeries for treatment. It was noticed that approximately 1.3 million people die each year because of road traffic crashes. Additionally, rising disposable income per capita among people across the globe is resulting into better treatment for injuries and rising demand for adult stem cells such as, mesenchymal stem cells. It was noticed that, globally the disposable income per capita in 2020 was USD 8784. Hence, this is anticipated to be a significant factor to propel the growth of the global mesenchymal stem cell (MSC) market during the forecast period.

Regionally, the global mesenchymal stem cell (MSC) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The North America region witnessed noteworthy growth in the global market for mesenchymal stem cell (MSC) in the year 2021. This growth can be accredited to the large number of aging population, and increasing incidence of cancers in the region. For instance, in the United States, 1,752,735 new cases of cancer were reported in 2019, while 599,589 people passed away from the disease. Additionally, the increasing research and development activities, rising healthcare expenditure, and presence of key market players in the region are estimated to drive the market growth over the forecast period.

Browse to access In-depth research report on the Global Mesenchymal Stem Cell (MSC) Market with detailed charts and figures: https://www.kennethresearch.com/report-details/mesenchymal-stem-cells-market/10082369

On the other hand, the global mesenchymal stem cell (MSC) market in the Asia Pacific region is expected to grow with the highest CAGR during the forecast period on the back of increasing number of aging patients, governments initiative such as check-up camps, patient friendly medical policies, and sufficient funding to healthcare sector. According to the Asian Development Bank, the number of elderly persons in the Asia Pacific region will reach 1.3 billion by 2050. For a clearer understanding, one in four persons will be older than 60. Among the Asia Pacific countries, China and India are expected to be the fastest growing MSC markets in the region owing to the rising geriatric population and increasing research and development initiatives in these regions.

The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Get a Sample PDF of the Global Mesenchymal Stem Cell (MSC) Market @ https://www.kennethresearch.com/sample-request-10082369

The global mesenchymal stem cell (MSC) market is segmented on the basis of application into disease modelling, oncology disorders, drug development & discovery, stem cell banking, tissue engineering, and others. Out of these, the oncology disorder segment is anticipated to hold the largest share in the market by the end of 2031 and is expected to grow at the highest CAGR during the forecast period. The growth of this segment can be majorly accredited to increasing cancer cases, wherein the branch of oncology deals with the prevention, treatment, and diagnosis of cancer. Additionally, upsurge in the number of cancer patients and cancer caused deaths worldwide is expected to be a major factor to fuel the growth of this segment over the forecast period. According to the World Health Organization, nearly 10 million people died of cancer across the globe in 2020.

Furthermore, the global mesenchymal stem cell (MSC) market is segmented based on stem cells indication into cardiovascular disease, liver disease, cancer, and others. Out of these, the cancer segment is anticipated to hold a substantial market share over the forecast period on the back of the increasing prevalence of cancer around the globe, and rising deaths caused by various types of cancer. It was noted that, in 2020, lung cancer caused 1.80 million deaths, colon and rectum cancer caused 916 000 deaths, liver cancer caused 830 000 deaths, and breast cancer caused 685 000 deaths across the globe.

The global mesenchymal stem cell (MSC) market is also segmented on the basis of treatment type, product & service, and source of isolation

Global Mesenchymal Stem Cell (MSC) Market, Segmented by Treatment Type

Global Mesenchymal Stem Cell (MSC) Market, Segmented by Product & Service

Global Mesenchymal Stem Cell (MSC) Market, Segmented by Source of Isolation

Bone Marrow

Cord Blood

Peripheral Blood

Lungs

Others

Enquiry before Buying This Report @ https://www.kennethresearch.com/sample-request-10082369

Some of the prominent players and their company profiling mentioned in the report include Cell Applications, Inc., Celprogen Inc., STEMCELL Technologies Inc., Axol Bioscience Ltd., Cytori Therapeutics Inc., Proteona Pte. Ltd., BrainStorm Cell Limited, Stemedica Cell Technologies, Inc., Mesoblast Ltd., ScienCell Research Laboratories, Inc., Neuromics, Inc., and others. The profiling enfolds growth opportunities, challenges, market trends, competitive analysis and positioning, along with the strategies used by them to stay ahead of their competitors.

Browse More Related Reports:

Thyroid Disorder Market Analysis by Disorder Type (Hypothyroidism, and Hyperthyroidism); by Treatment Type (Medications, Radioactive Iodine Therapy, and Surgery); by Route of Administration (Oral, and Intravenous); and by End-User (Hospitals, and Clinics)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031

Clinical Laboratory Services Market Analysis by Service Provider (Clinic-Based, Hospital-Based, and Independent Laboratories); and by Test Type (Hematology, Human & Tumor Genetics, Cytology, Immunology, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031

Disposable Syringes Market Segmentation by Type (General/Conventional, Safety, and Pre-Filled Syringes); by Syringe Tip (Luer-Lock, Slip, Eccentric, and Catheter Syringe Tips); by Application (Immunization, and Therapeutic Injections, and Others); by End-User (Hospitals, Diagnostic Laboratories, Blood Banks, Pharmaceutical Companies, and Others)-Global Demand Analysis & Opportunity Outlook 2021-2031

Medical Nutrition Market Analysis by Product Type (Enteral, Oral Supplements, and Parenteral Nutrition); by End Users (Pediatric, and Adult Nutrition); and by Distribution Channels (Hospitals, Retail Pharmacies, and E-commerce Websites)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031

Laparoscopy Devices Market Analysis by Application (Gynecological, Urological, General, Bariatric, and Other Surgery); by End Users (Ambulatory, Hospital, and Clinic); and by Product (Robotic Assisted Systems, Laparoscopes, Hand Access Instruments, Energy Systems, and Others)-Global Supply & Demand Analysis & Opportunity Outlook 2022-2031

About Kenneth Research

Kenneth Research is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@kennethresearch.com

U.S. Phone: +1 313 462 0609

Web: https://www.kennethresearch.com/

Read more:
Global Mesenchymal Stem Cell (MSC) Market to Grow at a CAGR of ~14% during 2022-2031; Market to Grow on the Back of Increasing Prevalence of Chronic...

Raising the dead sounds like science fiction, but a team of medical scientists at Yale University have managed to achieve just thatat least on a cellular level. They successfully revived cells from pigs that were dead for an hour, as a Nature study published August 3 reports. While the study authors emphasize the technology is ages away from being used on people, the work could eventually help keep human tissues alive longer, increasing the supply of viable organs for transplants.

These cells are functioning hours after they should not be, said Nenad Sestan, a professor of neuroscience and comparative medicine at Yale and lead author of the study, in a news briefing per CNN. And what this tells us is that the demise of cells can be halted. And their functionality restored in multiple vital organs. Even one hour after death.

Sestan and his colleagues received 100 pigs from a local breeder. They placed the pigs on ventilators and shocked the animals hearts to induce cardiac arrest. An hour after confirmed death, the Yale scientists used two systems to pump blood back into the bodiesan ECMO machine removed carbon dioxide and added oxygenated blood to one group, while another device, called OrganEx, pumped artificial blood back into the other. That fluid entered the blood vessels of the dead pigs, where synthetic forms of hemoglobin and other molecules protected cells from degradation and stopped blood clots.

After six hours, the researchers recorded signs of oxygen recirculating into the pigs tissues. A heart scan confirmed signs of electrical activity in the heart of pigs on the OrganEx machine, though those organs did not fully restart. Elsewhere, there were signs of business as usual, too: The livers of the deceased pigs resumed production of a protein called albumin. Additionally, the cells of other vital organs were responsive to glucose, suggesting the pigs metabolic processes were working again.

The experiment is not the first time scientists have tried to redefine life and death. In the early 20th century, there were attempts to reboot the brains of deceased monkeys. And in 2019, neuroscientists reanimated the brains of decapitated pigs four hours after they died in a slaughterhouse.

Studies such as these raise questions about what it means to be dead. We presume death is a thing, it is a state of being, Nita Farahany, a Duke law professor who studies ethical, legal and social implications of emerging technologies, told The New York Times. Are there forms of death that are reversible? Or not?

The findings also call into question who is considered legally dead, especially as medicine adapts to make cardiac death one day reversible. People tend to focus on brain death, but theres not much consensus on when cardiac death occurs, Arthur Caplan, a bioethicist at New York University told Nature News. This paper brings that home in an important way.

Ethical challenges abound if technology such as this were applied to people. In 2016 Indias medical research council, citing ethical concerns, blocked a planned clinical trial that aimed to revive brain-dead people to a minimally conscious state using a mix of stem cells and other techniques.

While the current study showed no signs of brain activity in the pigs, the researchers observed the heads, necks, and torsos moved. If brain activity was restored, there is no telling how functional or conscious the pigs would be, making it one of a slew of ethical questions scientists will need to answer as they breach this murky area of science.

Here is the original post:
Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science